Abstract:Plastic surgery procedures in which large detachment is planned in patients with a moderate risk of deep venous thrombosis should be evaluated with regard to the risk and benefit of thromboembolism prophylaxis. Other measures must be applied and eventually contraindicate a surgical procedure. Further research is needed to complement the data from this work.
“…20 Because of this study's small size and inability to pool data, we cannot make recommendations on this class of drugs. The oral factor Xa inhibitor apixaban has U.S. Food and Drug Administration approval for stroke reduction in nonvalvular atrial fibrillation and for deep venous thrombosis and pulmonary embolus prophylaxis after adult hip or knee replacement.…”
Section: Target Questions 3 and 4: What Is The Effectiveness And Bleementioning
confidence: 98%
“…Five studies were randomized controlled trials. [20][21][22][23][24] The study by Ashjian et al 25,26 was a prospective cohort study, the study by Harbottle et al 27 was a prospective case-control study, and the study by Reinisch et al 28 was a randomized postal survey of clinical practice in face-lift surgery. The remaining 19 studies were retrospective cohort studies.…”
“…20 Because of this study's small size and inability to pool data, we cannot make recommendations on this class of drugs. The oral factor Xa inhibitor apixaban has U.S. Food and Drug Administration approval for stroke reduction in nonvalvular atrial fibrillation and for deep venous thrombosis and pulmonary embolus prophylaxis after adult hip or knee replacement.…”
Section: Target Questions 3 and 4: What Is The Effectiveness And Bleementioning
confidence: 98%
“…Five studies were randomized controlled trials. [20][21][22][23][24] The study by Ashjian et al 25,26 was a prospective cohort study, the study by Harbottle et al 27 was a prospective case-control study, and the study by Reinisch et al 28 was a randomized postal survey of clinical practice in face-lift surgery. The remaining 19 studies were retrospective cohort studies.…”
“…Potentially more varied than the opinions over who is most at risk of venous thromboembolism are those relating to how and when to administer prophylaxis. 16,[23][24][25] The literature disagrees about the risks of bleeding associated with venous thromboembolism chemoprophylaxis. Hatef et al found an increased rate of hematoma following prophylaxis with enoxaparin in body contouring patients.…”
“…Given the fact that obesity and smoking status are associated with pulmonary embolism [24], it is similarly important to note that the three patients who experienced a pulmonary embolism in our study had an average BMI of 45.7 and one had a history of smoking (33.3 %). Greater thromboprophylaxis precautions should be taken in patients who wish to undergo a combined procedure, particularly if they have additional risk factors for venous thromboembolism [25].…”
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.